Axcentua Pharmaceuticals is an innovative drug discovery and development company located at the Karolinska Institute Science Park. Axcentua is pioneering a unique strategy, crystal re-engineering, for accelerated development of novel therapeutics to the clinic. The core business idea and competitive advantage is to decrease drug development times and the risk for failure in the clinic by using natural compounds. Our lead compound, AXP107-11, is a multi-targeted crystal re-engineered natural compound, currently in clinical trials for pancreatic cancer, targeting the complex fibrotic desmoplasia of the pancreatic tumors making the tumors more accessible to chemotherapy. IP protection of the crystalline form, the crystallization process, composition of matter, and therapeutic use of AXP107-11 is secured through a recent US patent and a pending PCT. Pipeline expansion through novel formulations of AXP107-11 as well as crystal re-engineering of backup candidates is ongoing. Our development strategy enables a fast proof of principle of candidate drugs in the clinic, leading to early value enhancement and commercial opportunities.
